Expertise in
1
conditions

Miguel A. Fandino-Quintela

Almagro, MD, ES 
Expertise in
1
conditions
Almagro, MD, ES 

Overview

Miguel Fandino-Quintela practices practicing medicine in Almagro, Spain.

Mr. Fandino-Quintela is highly rated in 1 condition, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Ovarian Cancer, and Cerebral Hypoxia.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Almagro, MD, Spain
Other Locations
Madrid, MD, Spain
Fuenlabrada, MD, Spain
Pozuelo De Alarcon, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase IB Clinical Trial of Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer With Hyperactivation of ERK and/or CDK4/6
Phase IB Clinical Trial of Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer With Hyperactivation of ERK and/or CDK4/6
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Binimetinib
Study Phase: Phase 1/Phase 2
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drugs: Rogaratinib, Palbociclib, Fulvestrant
Study Phase: Phase 1
View 1 Less Clinical Trial

51 Total Publications

FASN targeting by G28UCM impairs mitochondrial fatty acid synthesis and reveals a FASN-SDHB synthetic interaction.
FASN targeting by G28UCM impairs mitochondrial fatty acid synthesis and reveals a FASN-SDHB synthetic interaction.
Journal: Pharmacological research
Published: October 31, 2025

Frequently Asked Questions about Miguel A. Fandino-Quintela

Is Miguel A. Fandino-Quintela a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Miguel A. Fandino-Quintela is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Miguel A. Fandino-Quintela participate in research or clinical trials?

Yes. Miguel A. Fandino-Quintela has published 51 articles and abstracts on conditions like Breast Cancer. You can view a list of Miguel A. Fandino-Quintela's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fandino-Quintela's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile